On May 7, 2026, the U.S. Food and Drug Administration (FDA) released a new version of the "Digital Labeling & Website Compliance Guidance v3.1," requiring all foreign manufacturers exporting medical devices to the United States to embed a verifiable API interface on their company website's product pages that synchronizes FDA registration/listing status in real time, and supports dynamic display in English, Spanish, and French. This adjustment directly impacts medical device manufacturers, export traders, and import compliance service providers in major exporting countries such as China, as it will be directly linked to the importer due diligence list implemented from the third quarter of 2026, becoming a key technical hurdle for U.S. factory inspections, customs clearance, and procurement assessments.

Event Overview

On May 7, 2026, the U.S. FDA officially released "Digital Labeling & Website Compliance Guidance v3.1". The document clarifies that all foreign manufacturers selling medical devices in the U.S. must integrate an FDA-approved registration/listing status API with real-time data synchronization capabilities into their official website's product pages; the API output must support automatic switching and dynamic rendering in English, Spanish, and French; these technical requirements will be included in importers' due diligence checklists for foreign suppliers starting in the third quarter of 2026.

Which sub-sectors will be affected?

Direct trading enterprises

For companies engaged in the direct export of medical devices to the US, their official websites are the core channel for US purchasers to conduct initial qualification screening. Analysis shows that this requirement essentially upgrades the website from an information display platform to a verifiable carrier of compliance credentials—failure to complete API embedding or language adaptation on time may lead US importers to consider the company's qualifications questionable, resulting in delayed inquiry responses, order postponements, or failure to pass due diligence.

Processing and manufacturing enterprises

While OEM/ODM manufacturers do not directly serve end customers, they are often required to disclose their partner brands and corresponding FDA registration information on their official websites. It appears that if their websites do not embed APIs and support trilingual displays as required by the new regulations, they will struggle to meet brands' compliance requirements regarding the transparency of their supply chain, potentially impacting their eligibility for long-term partnerships.

Supply chain service companies

Service providers offering FDA registration agency services, compliance consulting, and digital compliance system deployment must ensure their technical solutions are compatible with the v3.1 API integration specification and multi-language rendering logic. From an industry perspective, existing traditional delivery methods such as static web page filing and PDF registration certificate uploads are no longer sufficient to meet the new regulations; service capabilities need to be upgraded towards API integration and front-end localization.

What key areas should relevant enterprises or practitioners focus on, and how should they respond at present?

Pay attention to the FDA's subsequent release of API technical specification documents and certification whitelists.

More importantly, the FDA has not yet publicly disclosed the specific API call protocol, authentication mechanism, or list of authorized access service providers. Companies should continuously monitor updates to the FDA's "Medical Device Registration and Listing" section on its website to avoid using unofficial recommended paths that could lead to data inconsistencies or verification failures.

Prioritize implementation for key product categories to avoid a "one-size-fits-all" approach to reform.

The new regulations are not implemented in phases according to risk levels. However, in practice, high-risk products (Class II/III) and those already in the US market with customs clearance records will be the first to be inspected by importers. Companies should prioritize configuring API interfaces for their main models that are already registered and continuously shipping, rather than extending them to all historical products.

Confirm whether the existing website's technical architecture supports multi-language dynamic rendering and real-time status feedback.

Some company websites are built on static HTML or outdated CMS, which cannot natively support asynchronous API loading and automatic language environment recognition. It's more appropriate to understand this as needing to assess the compatibility of the front-end framework (such as whether it supports JavaScript dynamic injection and i18n multi-language modules), and introduce lightweight, compliant plugins if necessary, rather than completely rebuilding the site.

Simultaneously update internal compliance communication scripts and external document specifications.

Purchasers, importers, and third-party auditing agencies will conduct inquiries based on the API results displayed on the official website. Enterprise quality and international business departments must maintain consistent internal communication and clearly define the legal validity of the status displayed by the API (e.g., it only reflects registration/listing validity and is not equivalent to 510(k) or PMA approval status) to avoid compliance misunderstandings due to interpretation discrepancies.

Editor's Viewpoint / Industry Observation

Observably, this update is not an isolated technical adjustment, but rather a continuation of the FDA's efforts to promote digital regulation of the entire medical device supply chain. Following electronic registration, eCopy submission, and the mandatory implementation of the UDI system, the official website is now positioned as a "digital compliance interface for enterprises." Analysis shows that this requirement currently resembles a strong signal rather than an immediate penalty: it does not yet set explicit penalties, but it is already embedded in the importer's compliance obligations system, meaning that the pressure to implement it will be transmitted from downstream to upstream. What the industry needs to continue to pay attention to is the practical feedback from the first batch of companies sampled after Q3 2026, and whether the FDA will include API availability in the appendix to the on-site inspection memo.

Conclusion

This update to the FDA's compliance guidelines marks the formal inclusion of the digital infrastructure of overseas medical device manufacturers into the U.S. regulatory assessment framework. Its industry significance lies not in adding a separate certification, but in integrating fragmented compliance actions (registration, listing, labeling, website) into a unified, verifiable digital interface. Currently, it's more appropriate to understand this as a process upgrade oriented towards "verifiability." Companies do not need to panic and implement changes, but they should prioritize API integration in their compliance work for the second half of 2026, focusing on the intersection of actual shipped products, actual purchaser needs, and actual technical feasibility.

Information source explanation

Primary source: The U.S. FDA's "Digital Labeling & Website Compliance Guidance v3.1" (effective May 7, 2026). Areas to be monitored: The FDA has not yet released detailed rules for API technology access, a whitelist of certified service providers, and specific implementation samples of due diligence for importers starting in Q3 2026.